Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
Bushra TbakhiPatrick M ReaganPublished in: Therapeutic advances in hematology (2022)
Mantle cell lymphoma (MCL) is a rare B-cell malignancy that remains challenging to treat with high rates of relapse. Frontline strategies range from intensive chemotherapy followed by consolidation with autologous stem cell transplant (ASCT), to less-intensive therapies including combination regimens. The treatment landscape for relapsed patients includes Bruton tyrosine kinase (BTK) inhibitors among other targeted treatments. Novel agents such as the selective BCL2 inhibitor venetoclax showed high response rates when used as monotherapy for refractory relapsed MCL. The rituximab, bendamustine, and cytarabine (R-BAC) regimen, while response rates were high, were not durable. Chimeric antigen receptor (CAR) T-cell products targeting CD19 have been efficacious in relapsed and refractory MCL patients. Brexucabtagene autoleucel (brexu-cel, formerly KTE-X19) was approved by US Food and Drug Administration (FDA) in July, 2020, for treatment of refractory and relapsed MCL. This article provides an overview for the available management strategies for relapsed MCL and examines the role of CAR T-cell in the current and future treatment of MCL.
Keyphrases
- acute myeloid leukemia
- acute lymphoblastic leukemia
- tyrosine kinase
- diffuse large b cell lymphoma
- stem cells
- hodgkin lymphoma
- multiple myeloma
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- combination therapy
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- single cell
- prognostic factors
- drug administration
- cancer therapy
- low dose
- mesenchymal stem cells
- study protocol
- current status
- climate change
- patient reported
- double blind
- chemotherapy induced